Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group

被引：0
|
作者：
C. I. Müller
K. Schulmann
A. Reinacher-Schick
N. Andre
D. Arnold
A. Tannapfel
H. Arkenau
S. A. Hahn
S. H.-J. Schmoll
R. Porschen
W. Schmiegel
U. Graeven
机构：
[1] University Hospital Essen,Institute of Physiology
[2] Ruhr-University of Bochum,Medical Department
[3] Martin Luther University,Medical Department IV, University Clinic
[4] Ruhr-University of Bochum,Institute of Pathology, University Clinic Bergmannsheil
[5] Royal Marsden Hospital and Institute of Cancer Research,Drug Development Unit
[6] Ruhr-University of Bochum,Center for Clinical Research (ZKF, Molecular GI
[7] Medical Department Klinikum Bremen-Ost,Oncology (MGO))
[8] Ruhr-University of Bochum,Division of Gastroenterology and Hepatology, University Hospital Bergmannsheil
[9] Kliniken Maria Hilf GmbH Klinik für Hämatologie,undefined
[10] Onkologie,undefined
[11] Gastroenterologie,undefined
来源：
International Journal of Colorectal Disease | 2008年 / 23卷
关键词：
Colorectal cancer; Microsatellite instability; Chemotherapy; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1033 / 1039
页数：6
相关论文
共 50 条
  • [11] Identification of an immunological prognostic factor for metastatic colorectal cancer patients treated with first-line oxaliplatin-based chemotherapy
    Tada, K.
    Shoji, H.
    Kitano, S.
    Nishimura, T.
    Shimada, Y.
    Nagashima, K.
    Ito, A.
    Honma, Y.
    Iwasa, S.
    Okita, N.
    Takashima, A.
    Kato, K.
    Yamada, Y.
    Katayama, N.
    Boku, N.
    Heike, Y.
    Hamaguchi, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S80 - S80
  • [12] Mucinous histology in advanced colorectal cancer patients treated with first-line irinotecan- and/or oxaliplatin-based chemotherapy
    Catalano, V.
    D'Emidio, S.
    Loupakis, F.
    Graziano, F.
    Torresi, U.
    Mari, D.
    Bisonni, R.
    Giordani, P.
    Giustini, L.
    Falcone, A.
    Silva, R. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [13] Prognostic and predictive value of microsatellite instability status among patients with colorectal cancer
    Baidoun, Firas
    Saad, Anas M.
    Abdel-Rahman, Omar
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (16) : 1197 - 1214
  • [14] PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients
    Vincenzi, Bruno
    Santini, Daniele
    Perrone, Giuseppe
    Graziano, Francesco
    Loupakis, Fotios
    Schiavon, Gaia
    Frezza, Anna Maria
    Ruzzo, Anna Maria
    Rizzo, Sergio
    Crucitti, Pierfilippo
    Galluzzo, Sara
    Zoccoli, Alice
    Rabitti, Carla
    Muda, Andrea Onetti
    Russo, Antonio
    Falcone, Alfredo
    Tonini, Giuseppe
    JOURNAL OF CELLULAR PHYSIOLOGY, 2012, 227 (03) : 927 - 933
  • [15] JAPANESE COHORT STUDY OF FIRST LINE CHEMOTHERAPY (CT) FOR METASTATIC COLORECTAL CANCER (MCRC) CONTAINING FLUOROPYRIMIDINE, OXALIPLATIN AND BEVACIZUMAB: EMERALD STUDY, FIRST REPORT
    Taku, K.
    Ohata, K.
    Yamazaki, K.
    Nishikawa, G.
    Watanabe, M.
    Sato, S.
    Oshima, T.
    Hirano, H.
    Amano, T.
    Ohashi, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 220 - 220
  • [16] Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy
    A Ruzzo
    F Graziano
    F Loupakis
    D Santini
    V Catalano
    R Bisonni
    R Ficarelli
    A Fontana
    F Andreoni
    A Falcone
    E Canestrari
    G Tonini
    D Mari
    P Lippe
    F Pizzagalli
    G Schiavon
    P Alessandroni
    L Giustini
    P Maltese
    E Testa
    E T Menichetti
    M Magnani
    The Pharmacogenomics Journal, 2008, 8 : 278 - 288
  • [17] Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy
    Ruzzo, A.
    Graziano, F.
    Loupakis, F.
    Santini, D.
    Catalano, V.
    Bisonni, R.
    Ficarelli, R.
    Fontana, A.
    Andreoni, F.
    Falcone, A.
    Canestrari, E.
    Tonini, G.
    Mari, D.
    Lippe, P.
    Pizzagalli, F.
    Schiavon, G.
    Alessandroni, P.
    Giustini, L.
    Maltese, P.
    Testa, E.
    Menichetti, E. T.
    Magnani, M.
    PHARMACOGENOMICS JOURNAL, 2008, 8 (04): : 278 - 288
  • [18] THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS
    Maughan, T.
    Adams, R.
    Smith, C.
    Seymour, M.
    Wilson, R.
    Meade, A.
    Fisher, D.
    Madi, A.
    Cheadle, J.
    Kaplan, R.
    ANNALS OF ONCOLOGY, 2010, 21 : 17 - 18
  • [19] Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer
    Grapsa, Dimitra
    Syrigos, Konstantinos
    Saif, Muhammad Wasif
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (11) : 1267 - 1281
  • [20] Chemotherapy efficacy in metastatic colorectal cancer (mCRC) patients treated with adjuvant or first-line FOLFOX-based chemotherapy.
    Samalin, Emmanuelle
    Tien Tuan Nguyen
    Thezenas, Simon
    Portales, Fabienne
    Mazard, Thibault
    Gourgou, Sophie
    Assenat, Eric
    Ychou, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345